Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy
Recruiting
Columbia University
Phase 4
2020-02-28
Cerebral palsy (CP) is a common childhood-onset disability associated with motor and
cognitive impairments, however most research is focused on motor outcomes. The aim of this
study is to determine the effects of Amantadine, a dopaminergic agonist, on cognitive
function in adolescents and adults with CP.
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
Recruiting
Adamas Pharmaceuticals, Inc.
Phase 4
2020-11-05
The purpose of the study is to learn about the effect of GOCOVRI (Amantadine extended
release) on activity levels and measures of gait and balance quality in people with
Parkinson's disease (PD) and levodopa induced dyskinesia (LID) during daily activities using
body-worn sensors.
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
Recruiting
Oregon Health and Science University
Phase 4
2020-11-05
The purpose of the study is to learn about the effect of GOCOVRI (Amantadine extended
release) on activity levels and measures of gait and balance quality in people with
Parkinson's disease (PD) and levodopa induced dyskinesia (LID) during daily activities using
body-worn sensors.
Use of Gocovri to Improve Disability Due to Radiation Encephalopathy
NOT_YET_RECRUITING
Supernus Pharmaceuticals
PHASE2
2025-09-01
A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.
Use of Gocovri to Improve Disability Due to Radiation Encephalopathy
NOT_YET_RECRUITING
Weill Medical College of Cornell University
PHASE2
2025-09-01
A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
